Royalty Pharma is the largest dedicated buyer of biopharmaceutical royalties, and the mid-year print is a test of whether the post-internalization compounding model can keep growing recurring cash after the biggest franchise in the book stopped expanding. Recurring Royalty Receipts, the contractual share of other companies' drug sales, rose to $768 million. That print was strong enough for management to lift full-year Portfolio Receipts guidance a second time. The equity debate is not whether the collection machine still works. It is whether Vertex cystic fibrosis cash, now flat, plus a live rate fight on Alyftrek, leaves growth dependent on newer royalties that have not yet replaced the franchise's scale.
The cash engine and the GAAP income statement are telling different stories. Operating cash flow doubled because development-stage funding and cash operating costs both collapsed after the manager buy-in closed last May. GAAP operating income fell because a provision for lower expected royalty cash flows swung from a prior-year credit to a $268 million charge. Net income attributable to the plc fell to $18 million. That swing is accounting, not a cash leak, but it flags downward revisions on named assets such as Adstiladrin and the cystic fibrosis book. Shareholders who treat GAAP earnings as the scorecard miss the internalization benefit and over-weight a non-cash forecast rewrite.
Guidance now sits at $3.4 billion to $3.5 billion of Portfolio Receipts. That range implies Royalty Receipts growth in the high single digits after Promacta generics, a United States Tysabri biosimilar, and Inflation Reduction Act scenarios. Capital deployment year to date is already above $1 billion, led by the Neurimmune slice of AstraZeneca's cliramitug. The question for the next several quarters is whether Tremfya, Voranigo, Imdelltra, and the late-stage book can keep covering a flat cystic fibrosis franchise while the Alyftrek rate fight stays unresolved.